Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAFIERTAM vs CHEMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.
Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.
FDA-approved: Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,Off-label: None widely documented.
Treatment of acute and chronic lead poisoning,Treatment of mercury poisoning,Treatment of arsenic poisoning,Diagnostic chelation challenge test
120 mg orally once daily.
10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.
Approximately 12 hours (range 8–15 hours); permits twice-daily dosing in multiple sclerosis.
Terminal elimination half-life: 1.6–3.5 hours (mean 2.1 h) in adults with normal renal function; prolonged in renal impairment (up to 20 h).
BAFIERTAM is a prodrug that is rapidly metabolized by esterases in the gastrointestinal tract, blood, and tissues to monomethyl fumarate. Monomethyl fumarate is further metabolized via the tricarboxylic acid (TCA) cycle, with no significant involvement of cytochrome P450 enzymes.
Metabolized in liver to disulfide dimers; undergoes enterohepatic circulation; primarily excreted renally as metabolites and unchanged drug.
Primarily via renal excretion as unchanged drug (approximately 80% of the dose); minimal biliary/fecal elimination (<5%).
Renal: 80–90% as unchanged drug and metabolites (primarily as chelated complexes); biliary/fecal: <10%.
30–40% bound to plasma proteins, primarily albumin.
Approximately 80% bound to plasma proteins, primarily albumin.
Approximately 0.5–0.7 L/kg; indicates distribution into total body water with limited tissue binding.
0.5–0.8 L/kg, indicating distribution mainly in extracellular fluid; limited intracellular penetration.
Oral: Approximately 50% (due to first-pass metabolism); administer with food to reduce GI irritation.
20–40% after oral administration due to first-pass metabolism and limited absorption.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
GFR 50-80 m L/min: same dose every 12 hours. GFR 10-49 m L/min: same dose every 24 hours. GFR <10 m L/min: same dose every 48 hours.
Use with caution in hepatic impairment; reduce dose to 60 mg once daily in Child-Pugh Class B or C.
No specific recommendations; caution in severe hepatic impairment (Child-Pugh C) due to potential toxicity.
Not established in pediatric patients.
Children >1 year: 10-20 mg/kg/dose orally every 8 hours for 5 days; maximum 1250 mg/dose.
No specific dose adjustment; use with caution due to age-related decline in renal function.
Consider starting at lower end of dosing range (10 mg/kg) due to potential renal impairment; adjust per renal function.
No black box warning.
None
Lymphopenia: May cause reduction in lymphocyte counts; monitor complete blood count before and periodically during treatment.,Hypersensitivity reactions: Anaphylaxis and angioedema may occur; discontinue if severe.,Progressive multifocal leukoencephalopathy (PML): Reported in patients with prolonged lymphopenia; consider holding therapy if lymphocyte counts drop below 0.2 x 10^9/L.,Hepatic injury: Elevations of liver enzymes have been reported; monitor in patients with pre-existing liver disease.,Flushing and gastrointestinal events: Common; may be managed by taking with food or using aspirin.
May cause nephrotoxicity; monitor renal function,May cause hypersensitivity reactions, including fever, rash, and anaphylaxis,Monitor for neutropenia; obtain CBC before and during therapy,Use caution in patients with hepatic impairment or glucose-6-phosphate dehydrogenase (G6PD) deficiency,May chelate essential minerals (e.g., zinc, copper); monitor levels with prolonged use,Not recommended for routine use in asymptomatic lead poisoning with low blood lead levels
Known hypersensitivity to BAFIERTAM, monomethyl fumarate, or any excipient.,Concomitant use with dimethyl fumarate or other fumaric acid esters.
Hypersensitivity to dimercaprol or any component of the formulation,Hepatic failure (except severe heavy metal poisoning),Concurrent use with iron (increases nephrotoxicity); avoid iron therapy within 24 hours,Pregnancy (if not life-saving indication due to risk of teratogenicity),Peanut allergy (formulation contains peanut oil)
Administer with food to reduce flushing and gastrointestinal adverse effects. Avoid alcohol consumption during treatment as it may exacerbate flushing. No specific dietary restrictions are required.
No specific food interactions reported. However, due to gastrointestinal side effects (nausea, vomiting), it is advisable to maintain small, frequent meals. Avoid alcohol.
BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic potential.
FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimesters: No specific teratogenicity, but may cause anemia in fetus due to maternal chelation of essential metals. Avoid use unless clearly needed.
No data on presence in human milk. M/P ratio unknown. Risk of infant exposure cannot be excluded. Discontinue breastfeeding or drug, considering importance to mother.
No human data on excretion in breast milk. M/P ratio unknown. Caution due to potential for infant exposure and chelation of trace elements; consider benefit-risk. Avoid breastfeeding during therapy and for 2 weeks after last dose.
No dose adjustment data; contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately. Pharmacokinetic changes unknown but drug should not be used.
No specific dose adjustments recommended for pregnancy. Increased plasma volume in pregnancy may alter pharmacokinetics, but studies not performed. Use lowest effective dose; monitor therapeutic response and toxicity closely.
BAFIERTAM (monomethyl fumarate) is a prodrug of monomethyl fumarate, indicated for relapsing forms of multiple sclerosis. Administer with food to reduce flushing and gastrointestinal adverse effects. Titrate as per recommended schedule to improve tolerability. Monitor complete blood count, liver function tests, and renal function at baseline and periodically. Flushing may be reduced by taking with food or using non-enteric coated aspirin (325 mg) 30 minutes prior. Avoid concurrent use with dimethyl fumarate or other fumaric acid esters.
Chelation therapy with dimercaprol (CHEMET) should be initiated within 4 hours of arsenic or mercury exposure for maximal efficacy. Administer only via deep intramuscular injection, never intravenously. Monitor renal function and urine output closely, as dimercaprol can cause nephrotoxicity. Alkalinize urine to p H 7.5-8.5 to decrease renal precipitation of metal-drug complexes. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolysis. Contraindicated in patients with peanut allergy (vehicle is peanut oil).
Take BAFIERTAM exactly as prescribed, usually twice daily with food.,Flushing and gastrointestinal upset are common but may decrease over time; taking with food and gradual dose titration helps.,Do not crush, chew, or open capsules; swallow whole.,Report any signs of infection, unusual bruising or bleeding, or severe abdominal pain to your healthcare provider.,Avoid consuming alcohol, as it may increase flushing risk.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose; do not double up.,Inform all healthcare providers that you are taking BAFIERTAM.
This medication is given as a shot into a muscle, usually in the buttock. It may cause pain at the injection site.,You may experience a metallic taste, nausea, vomiting, headache, or burning sensation in the mouth or throat.,Drink plenty of fluids unless otherwise instructed to help flush metals from your body.,Avoid alcohol during treatment and for at least 48 hours after the last dose.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or dark urine immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAFIERTAM vs CHEMET, answered by our medical review team.
BAFIERTAM is a Iron Chelating Agent that works by BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.. CHEMET is a Chelating agent that works by Chelates heavy metals, particularly lead, mercury, and arsenic, by forming soluble complexes that are excreted renally. Acts as an antidote by binding to toxic metals and reducing their tissue concentrations.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAFIERTAM and CHEMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAFIERTAM is: 120 mg orally once daily.. The standard adult dose of CHEMET is: 10-20 mg/kg orally every 8 hours for 5 days; maximum single dose 1250 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAFIERTAM and CHEMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAFIERTAM is classified as Category C. BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic p. CHEMET is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies, but animal studies show fetal resorption at maternally toxic doses, risk cannot be excluded. Second and third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.